Attack the cancer, not the patient
Our innovative technology provides a step-change in the selectivity and potency of targeted cancer drugs
As novel biotherapeutics progress through the clinic and on to the market, toxicities generated due to the expression of the targeted antigens on healthy tissues represent a key concern linked with significant long-term morbidities and mortality.
Through direct experience in the NHS and with a leading Antibody Drug Conjugate ("ADC") sector specialist, the BiVictriX team has developed the Bi-Cygni technology. Bi-Cygni therapeutics target a novel cancer-restricted cell-surface fingerprint, which is absent from healthy cells. Enabling the development of anti-cancer drugs with a marked increase in tumour selectivity, together with improved potency.
Problem: Lack of truly tumour-specific antigens available